NEW STUDY from cancer network!

"• Median OS with Avastin plus PC was 12.3 months vs 10.3 months with PC alone (HR=0.80 [95% CI, 0.68–0.94], P=0.013)1 • Patients receiving Avastin plus PC vs PC alone were 16% more likely to be alive at 1 year (51% vs 44%) and 53% more likely to be alive at 2 years (23% vs 15%)2 • Avastin plus PC demonstrated a median progression-free survival of 6.2 months (vs 4.5 months with PC alone, HR=0.66 [95% CI, 0.57-0.77], P<0.001) in Study E4599, based on investigator assessment (not independently verified)1,2 • Avastin plus PC had a response rate of 35% vs 15% with PC alone (P<0.001), based on investigator assessment (not independently verified)2

As shown in Study E4599, Avastin plus PC demonstrated an acceptable safety profile

Most common grade 3–5 adverse events in first-line metastatic non-squamous NSCLC patients (≥2% higher incidence in the Avastin arm)1"